amrcongbanner

Venus showcased its proprietary platform technology “Stealth Targeted Nanoparticles (STN)” at World AMR Congress-2018.


Healthcare-Associated Infections (HAIs) represent a huge burden of AMR in the developed world. Unfortunately, most drugs available to treat serious infections caused by gram-negative bacteria can only be administered intravenously as one or more of the active compounds have poor oral bioavailability. To overcome this hurdle, a new technology — Stealth Targeted Nanoparticles (STN) — is being developed to enable drugs such as Ceftazidime, Meropenem and BL-BLI combinations, etc. with poor bioavailability to be delivered orally.

image

Recent Events

blog1
AMR Congress 2018

Venus raised Indian voice against AMR and exhibited its innovative.

More
blog2
ASM/ESCMID Conference 2017

Venus presented the study results on the company's ARB approach.

More
blog3
ID Week 2018

VRL proudly announce to present results of plea Clinical Trial studies.

More

Copyright © 2019 VMRCINDIA All Rights Reserved